表紙
市場調査レポート

Colazal・Giazo(潰瘍性大腸炎) - 予測と市場分析

Colazal & Giazo (Ulcerative Colitis) - Forecast and Market Analysis to 2022

発行 GlobalData 商品コード 300499
出版日 ページ情報 英文 50 Pages
即納可能
価格
本日の銀行送金レート: 1USD=107.50円で換算しております。
Back to Top
Colazal・Giazo(潰瘍性大腸炎) - 予測と市場分析 Colazal & Giazo (Ulcerative Colitis) - Forecast and Market Analysis to 2022
出版日: 2014年02月28日 ページ情報: 英文 50 Pages
概要

2012年〜2022年の潰瘍性大腸炎(UC)治療薬市場は、Johnson & Johnson(Simponi)、武田薬品工業(Entyvio)の参入によって大幅な成長が予測され、主要国(米国、EU5ヶ国、日本、カナダ)において、生物製剤による治療を受ける患者数が増加すると見込まれています。また、UCのブロックバスター薬(Remicade、Humira)が米国で特許失効となるため、バイオシミラー(バイオ後続品)の発売が、市場に影響を与える可能性があります。

当レポートでは、UC治療薬であるColazal・Giazoについて調査分析し、疾病の概要と治療ガイドライン、競合情勢、製品情報、主要国の売上予測などを提供して、概略以下の構成でお届けいたします。

第1章 目次

第2章 イントロダクション

第3章 疾病の概要

  • 病因・病態生理
  • 症状

第4章 疾病の管理

  • 診断と治療の概要

第5章 競合評価

  • 概要
  • 戦略的競合企業の評価

第6章 Colazal・Giazo(balsazide disodium)

  • 概要
  • 効能
  • 安全性
  • SWOT分析
  • 予測

第7章 付録

図表

目次
Product Code: GDHC352DFR

During the forecast period from 2012-2022, the growth of the UC market will be driven largely by the entry of Johnson & Johnson's (J&J's) Simponi and Takeda's Entyvio, which will lead to an increase in the overall number of patients being treated with biologics in the US, 5EU, Japan, and Canada. Another key event affecting the UC market is the anticipated launch of biosimilars, given that the patent expiry of the UC blockbusters, Remicade and Humira are set to expire in the US in 2018 and 2016, respectively.

Colazal is an aminosalicylate prodrug. This means that its active ingredient, balsalazide disodium, contains an azo bond that can only be processed by bacterial azo reductases in the colon. Following its metabolism by the colonic commensal bacteria, mesalamine is released into and is restricted to the colon area, preventing the active ingredient from being systemically absorbed. Giazo is an aminosalicylate prodrug. This means that its active ingredient, balsalazide disodium, contains an azo bond that can only be processed by bacterial azo reductases in the colon. Following metabolism by the colonic commensal bacteria, mesalamine is released into and is restricted to the colon area, preventing the active ingredient from being systemically absorbed.

Scope

  • Overview of Ulcerative Colitis, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on Colazal & Giazo including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for Colazal & Giazo for the top three countries from 2012 to 2022.
  • Sales information covered for the US, Italy, and the UK.

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of the competition by understanding the changing competitive landscape for Ulcerative Colitis
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of Colazal & Giazo performance
  • Obtain sales forecast for Colazal & Giazo from 2012-2022 in the top three countries (the US, Italy, and the UK.)

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports
  • 2.3. Upcoming Related Reports

3. Disease Overview

  • 3.1. Etiology and Pathophysiology
    • 3.1.1. Etiology
    • 3.1.2. Pathophysiology
  • 3.2. Symptoms
    • 3.2.1. Quality of Life

4. Disease Management

  • 4.1. Diagnosis and Treatment Overview
    • 4.1.1. Diagnosis
    • 4.1.2. Treatment Guidelines and Leading Prescribed Drugs
    • 4.1.3. Clinical Practice

5. Competitive Assessment

  • 5.1. Overview
  • 5.2. Strategic Competitor Assessment

6. Colazal & Giazo (balsazide disodium)

  • 6.1. Overview
    • 6.1.1. Colazal
    • 6.1.2. Giazo
  • 6.2. Efficacy
    • 6.2.1. Colazal
    • 6.2.2. Giazo
  • 6.3. Safety
    • 6.3.1. Colazal
    • 6.3.2. Giazo
  • 6.4. SWOT Analysis
    • 6.4.1. Colazal
    • 6.4.2. Giazo
  • 6.5. Forecast
    • 6.5.1. Colazal
    • 6.5.2. Giazo

7. Appendix

  • 7.1. Bibliography
  • 7.2. Abbreviations
  • 7.3. Methodology
  • 7.4. Forecasting Methodology
    • 7.4.1. Diagnosed UC Patients
    • 7.4.2. Percent Drug-Treated Patients
    • 7.4.3. General Pricing Assumptions
    • 7.4.4. Individual Drug Assumptions
    • 7.4.5. Generic Erosion
  • 7.5. Physicians and Specialists Included in This Study
  • 7.6. Primary Research - Prescriber Survey
  • 7.7. About the Authors
    • 7.7.1. Author
    • 7.7.2. Global Head of Healthcare
  • 7.8. About GlobalData
  • 7.9. Disclaimer

List of Tables

  • Table 1: Genetic Factors That Confer a Predisposition to UC
  • Table 2: Typical Symptoms of UC
  • Table 3: Truelove and Witts UC Severity Index
  • Table 4: UCDAI
  • Table 5: Treatment Guidelines for UC Used in the 10MM
  • Table 6: Most Commonly Prescribed Drugs for UC by Class in the 10MM, 2013
  • Table 7: Leading Treatments for UC, 2014
  • Table 8: Product Profile - Colazal
  • Table 9: Product Profile - Giazo
  • Table 10: Colazal SWOT Analysis, 2014
  • Table 11: Giazo SWOT Analysis, 2014
  • Table 12: Global Sales Forecasts ($m) for Colazal, 2012-2022
  • Table 13: Global Sales Forecasts ($m) for Giazo, 2012-2022
  • Table 14: Annual Cost of Therapy for 5-ASAs ($)
  • Table 15: Physicians Surveyed, By Country

List of Figures

  • Figure 1: Cellular Mechanisms Involved in the Pathogenesis of UC
  • Figure 2: UC Disease Management Flowchart
Back to Top